Labiotech.eu (blog)CRISPR Does it Again! Gene Editing Tool Identifies a New Leukemia TargetLabiotech.eu (blog)Researchers from the Wellcome Trust Sanger Institute have reported that a new target for the treatment of leukemia has been found. A new drug … Continue reading
EPM MagazineERS Genomics Licenses CRISPR-Cas9 Patents to Charles River LaboratoriesGenomeWebNEW YORK (GenomeWeb) – ERS Genomics said today that it has signed a non-exclusive license agreement for its CRISPR-Cas9 patents with Charles River Laboratories… Continue reading
Fate Therapeutics, UC San Diego Launch CAR NK Cancer Immunotherapy CollaborationGenetic Engineering & Biotechnology NewsFate Therapeutics said today it will develop off-the-shelf, chimeric antigen receptor (CAR)-targeted natural killer (NK) cell cancer… Continue reading
Fate Therapeutics, UC San Diego Launch CAR NK Cancer Immunotherapy CollaborationGenetic Engineering & Biotechnology NewsFate Therapeutics said today it will develop off-the-shelf, chimeric antigen receptor (CAR)-targeted natural killer (NK) cell cancer… Continue reading
Endpoints NewsJuno inks deals with Eli Lilly, the Hutch as it looks to leapfrog leaders on BCMAEndpoints NewsLooking past the CD19 biomarker, BCMA offers one of the most promising targets in CAR-T. Look for this in a clinical trial, coming soon. “BCMA … Continue reading
Synthetic Biology Market Worth 8.84 Billion USD by 2022PR Newswire (press release)According to a new market research "Synthetic Biology Market by Tool (Oligonucleotides, Chassis Organisms, Enzymes), Technology (Genome Engineering, NGS, Cloning and… Continue reading
Biotech vet Gilman is back, heading up next-gen CAR-T startup ObsidianFierceBiotechAccording to Gilman, CAR-T cells exist “on a therapeutic knife edge, teetering between profound efficacy and brutal toxicity [and] they need to be tamed.” Obsidian is se… Continue reading
Endpoints NewsJuno Therapeutics Signs Licensing Agreements with Lilly, OncoTracker, and Fred Hutchinson Cancer Research Center …Business Wire (press release)SEATTLE–(BUSINESS WIRE)–Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company… Continue reading